Campbell & Co Investment Adviser’s Agilon Health AGL Stock Holding History

Campbell & Co Investment Adviser’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.58M	Buy	+14,754	New	+$966K	0.08%	390

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $895M AUM 792.56% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Belvedere Trading Chicago, Illinois $87.6B AUM 131.08% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

IMC Chicago Chicago, Illinois $419B AUM 72.04% 1-Year Est. Return

Campbell & Co Investment Adviser's AGL Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in Agilon Health (AGL) in Q2 2026: 14,754 shares worth $1.58M. The stake represents 0.08% of the portfolio and ranks #390 among its holdings.

43 funds tracked by Wall St. Rank hold AGL as of Q2 2026.

Campbell & Co Investment Adviser held 14,754 shares of Agilon Health worth $1.58M as of Q2 2026.
Agilon Health was a new Campbell & Co Investment Adviser position in Q2 2026.
Agilon Health made up 0.08% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #390 holding.
43 funds tracked by Wall St. Rank held Agilon Health as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.